Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone - Concepedia

Concepedia

Publication | Open Access

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

DOI Full Paper Access

677

Citations

33

References

2012

Year

Tina Green, Ken H. Young, Carlo Visco, Zijun Y. Xu‐Monette, Attilio Orazi, Ronald S. Go, Ole Nielsen, Ole Gadeberg, Torben Mourits‐Andersen, Mikael Frederiksen,

Journal of Clinical Oncology

Abstract

The immunohistochemical DHS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP.

References

	Year	Citations

Page 1